📉 Nikkei is down nearly 5% -> here are 43 recession-proof Japanese stocks from our screenerUnlock Now

Japan approves new stem cell-based Alzheimer's therapy

Published 19/01/2024, 11:28 am
© Reuters.  Japan approves new stem cell-based Alzheimer's therapy

In what could be a major breakthrough for Alzheimer's treatment, the Japanese Ministry of Health and Welfare has given the greenlight to a regenerative medicine technology based on administering fat-derived stem cells intravenously and into the spinal cord.

Developed by Korea's leading adult stem cell research institute, Biostar Stem Cell Research Institute, this new stem cell therapy involves administering 150-250 million stem cells intravenously and a further 50 million into the spinal cord cavity five times at intervals of two to four weeks.

“This is the first step in our project to overcome Alzheimer’s, which was launched with our commitment to conquer this disease,” Biostar Stem Cell Research Institute director Dr. Jeong-Chan Ra said.

“With the start of stem cell treatment, Biostar will support Alzheimer’s patients from all over the world – including Japan, Korea, China, and the US, starting in Japan – to restore their memory and ultimately their humanity.”

There are over 10 million new cases of dementia each year globally, with Alzheimer’s being the most common cause of the neurodegenerative disease.

Fundamental cure

Unlike most treatments for Alzheimer’s, which are limited to slowing the progression of disease, stem cell therapies are expected to offer a functional cure.

Testing on mice models revealed stem cell therapies offer a multi-pronged path of attack against Alzheimer's.

Mice who received the stem cell treatment improved in vital ways – cerebral vascular regeneration, and brain cell protection and regeneration were all observed following treatment, which also mediated the IL-10 cytokine.

IL-10 plays a central role in inflammation and neurological protection responses, particularly relevant given inflammation is considered to be one of the core contributors to cognitive decline.

An article by the BioSpectrum Bureau, a media platform for the healthcare and bioscience industry in the Asia Pacific region, stated: “No other compound or treatment has ever suggested so strongly the potential to prevent, as well as stop, this epidemic of incurable dementia sweeping across suffering patients and their families.”

Treatment has already begun at the Shinjuku Clinic in Tokyo, providing a sorely needed treatment pathway for those suffering from Alzheimer's.

Read more on Proactive Investors AU

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.